Journal of Cholesterol and Heart Disease

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Journal of Cholesterol and Heart Disease (2022) Volume 6, Issue 5

Application of beta-blockers and fracture risk

According to studies, the sympathetic nervous system depletes bone tissue. Adrenergic agonists induce bone desorption in mouse calvarias organ culture, according to in vitro evidence. Guanethidine, a sympathetic neurotoxic substance, is used in chemical sympathectomy to suppress preosteoclast development and disrupt osteoclast activation in adult rats. Additionally, in female rats with ovariectomies, the beta-blocker propranolol promoted bone growth. These findings imply that blockers may prevent postmenopausal women from losing bone mass. In fact, usage of blockers was linked to increased bone mineral density at the hip and forearm in women over 50, and use of beta-blockers was linked to a 30% reduction in fracture risk in a recent observational trial with 569 fracture case and 775 control patients. By lowering urine calcium excretion, thiazide diuretics are suggested to protect against bone loss. Numerous epidemiologic studies indicate that thiazide exposure is linked to a lower risk of fracture. To our knowledge, no studies have examined the relationship between -blocker use and the risk of fractures in men and young women or the combination of beta-blocker and thiazide diuretic use. In this extensive population based investigation, we investigated the relationship between the use of blockers with or without concurrent use of thiazides and the risk of fracture in men and women between the ages of 30 and 79.

Author(s): John Michele

Abstract Full Text PDF

Get the App